|
|
|
| Peripheral Blood miRNA Integrated Analysis on the Diagnostic Significance of miR-455-3p in Prostate Cancer |
| YAN Cheng-ming1, ZHU Guang-bin2, LI Chang-yong3, LI Ming-jie4 |
1. Fuzhou Center for Disease Control, Fuzhou Fujian 350005, China;
2. Department of Radiology, the Fifth Hospital of Guangzhou Medical University, Guangzhou Guangdong 510799, China;
3. Department of Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, China;
4. Affiliated Hospital of Qingdao University, Qingdao Shandong 266071, China |
|
|
|
|
Abstract Objective: To screen peripheral blood microRNA (miRNA) as biomarkers for prostate cancer diagnosis, the bioinformatics methods have been established. Methods: The miRNA differential expression dataset (GSE206793 and GSE112264) in the plasma of prostate cancer patients were downloaded on the website of GEO database. Firstly, the differential miRNAs in both of the two datasets were screened by bio-credit analysis. The screened miRNA was analyzed by KEGG signaling pathway and GO enrichment analysis. TF-miRNA network was constructed for upstream regulatory transcription factors. Subsequently, protein-protein interaction (PPI) network was constructed for target genes using STRING database. Finally, the expression levels of the differentially expressed miRNAs in different prostate cancer stages were analyzed in the two datasets. Results: This study found that miR-455-3p was differentially expressed in both datasets. Signal pathway analysis showed that miR-455-3p was enriched in different pathways, including autophagy, cell entry and neurotrophic factors. PPI network showed that the interacting proteins mainly included HDAC2, H2AFZ, SALL1, NCOR2, and MAP3K1. Moreover, miR-455-3p was significantly increased in prostate cancer patients with different stages and risk grades. The ROC curve results showed AUC values of 0.943 and 0.847 for the two datasets, respectively. Conclusion: This study proved that miR-455-3p in peripheral blood can be used as a biomarker for prostate cancer diagnosis.
|
|
Received: 05 June 2022
|
|
|
|
Corresponding Authors:
ZHU Guang-bin. E-mail: guangbin-zhu@qq.com
|
| About author:: #These authors contributed equally to this work. |
|
|
|
[1] Siegel RL, Miller KD, Jemal A.Cancer statistics[J].CA: A Cancer Journal for Clinicians,2019,69(1):7-34.
[2] Jansen FH, Roobol M, Jenster G, et al.Screening for prostate cancer in 2008 II: The importance of molecular subforms of prostate-specific antigen and tissue Kallikreins[J].European Urology,2009, 55(3):563-574.
[3] Jones MJ, Koeneman KS.Local-regional prostate cancer[J].Urologic Oncology: Seminars and Original Investigations,2008, 26(5):516-521.
[4] Bartel D.MicroRNAs: Target recognition and regulatory functions[J].Cell, 2009,136(2):215-233.
[5] Iorio MV, Croce CM.MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review[J].EMBO Molecular Medicine, 2012, 4(3):143-159.
[6] Bhayani M, Calin GA, Lai SY.Functional relevance of miRNA* sequences in human disease[J].Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis,2012, 731(1):14-19.
[7] Crowle E, Di Nicolantonio F, Loupakis F, et al.Liquid biopsy: monitoring cancer-genetics in the blood[J].Nature Reviews Clinical Oncology,2013, 10(8):472-484.
[8] Miyamoto DT, Lee RJ, Kalinich M, et al.An RNA-based digital circulating tumor cell signature is predictive of drug response and early dissemination in prostate cancer[J].Cancer Discovery,2018, 8(3):288-303.
[9] Clough E, Barrett T.The gene expression omnibus database[J].Methods Mol Bid, 2016, 1418:93-110.
[10] Urabe F, Matsuzaki J, Yamamoto Y,et al.Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer[J].Clinical Cancer Research,2019,25(10):3016-3025.
[11] Li J-H, Liu S, Zhou H, et al.StarBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data[J].Nucleic Acids Research,2014, 42(D1):D92-D97.
[12] Tong Z, Cui Q, Wang J, et al.TransmiR v2.0: an updated transcription factor-microRNA regulation database[J].Nucleic Acids Research,2019,47(D1):D253-D258.
[13] Zhao Y, Yan M, Yun Y, et al.MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer[J].Oncol Rep,2017, 37(4):2449-2458.
[14] Shan Z, Li Y, Yu S, et al.CTCF regulates the FoxO signaling pathway to affect the progression of prostate cancer[J].Journal of Cellular and Molecular Medicine,2019, 23(5):3130-3139.
[15] Yang Z, Pu M, Dong X, et al.CTCF-activated SNHG16 facilitates gastrointestinal stromal tumor by targeting miR-128-3p/CASC3 axis[J].Experimental Cell Research,2022,417(1):113131.
[16] Lundon DJ, Boland A, Prencipe M, et al.The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation[J].BMC Cancer,2017, 17(1):163.
[17] McIntyre MH, Kantoff PW, Stampfer MJ, et al. Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms[J].Cancer Epidemiology, Biomarkers & Prevention,2007, 16(11):2233-2236.
[18] Zhang Z, Chen W, Kang Y.et al.MIR-455-3P and HDACs co-regulate chondrogenesis[J].2016, 24: S224-S225.
[19] El-Amm J, Freeman A, Patel N, et al.Bone-targeted therapies in metastatic castration-resistant prostate cancer: Evolving paradigms[J].Prostate Cancer, 2013.
[20] Ito K.Prostate cancer in Asian men[J].Nature Reviews Urology,2014,11(4):197-212.
[21] Cannistraci A, Di Pace AL, De Maria R, et al.MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: Results from clinical data set and patients’ samples[J].BioMed Research International,2014:146170.
[22] Haldrup C, Kosaka N, Ochiya T, et al.Profiling of circulating microRNAs for prostate cancer biomarker discovery[J].Drug Delivery and Translational Research,2014, 4(1):19-30.
[23] McDonald A, Vira M, Shen J, et al. Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer[J].The Prostate,2018, 78(6):411-418.
[24] Srivastava A, Goldberger H, Dimtchev A, et al.Circulatory miR-628-5p is downregulated in prostate cancer patients[J].Tumor Biology,2014,35(5):4867-4873.
[25] Guo J, Liu C, Wang W, et al.Identification of serum miR-1915-3p and miR-455-3p as biomarkers for breast cancer[J].PLoS ONE,2018, 13:e0200716.
[26] Arai T, Kojima S, Yamada Y, et al.Pirin: a potential novel therapeutic target for castration-resistant prostate cancer regulated by miR-455-5p[J].Molecular Oncology, 2019,13(2):322-337. |
|
|
|
